 |
|
|
| |
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
|
| |
| |
- Latest Outcomes From HIV Prevention and Treatment Clinical Research, Including Data From Pivotal Phase 3 PURPOSE 1 & 2 Trials -
- Real World Evidence in COVID-19 Reinforce Veklury (remdesivir) as the Antiviral Standard of Care for the Treatment of People Hospitalized for COVID-19 -
- Investigational Obeldesivir Safety and Tolerability Data From BIRCH and OAKTREE Trials Support Continued Evaluation as a Potential Treatment Option for RSV -
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research and development programs at IDWeek 2024, taking place from October 16-19. The data from 31 presentations across HIV treatment and prevention, COVID-19 and viral hepatitis include one late breaker abstract and six oral presentations, reflecting Gilead's commitment to helping address the evolving needs of a diverse range of people and communities affected by some of the world's most challenging viruses.
https://www.gilead.com/news/news-details/2024/gilead-to-present-late-breaking-data-highlighting-antiviral-portfolio-innovative-research-pipeline-and-hiv-leadership-at-idweek-2024
HIV Research
Continuous scientific discovery in HIV is a pillar of Gilead's commitment to help end the HIV epidemic. Presented studies' results and analyses will include further evaluation of Biktarvy •(bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a long-term treatment option for a broad range of people with HIV (PWH). Outcomes from pipeline research studies will also provide insights into investigational treatment candidates, including new data on GS-1720, a novel once-weekly integrase strand transfer inhibitor (INSTI), and a late-breaker oral presentation of Week 48 data from the Phase 2 study evaluating an investigational once-weekly oral combination regimen of islatravir and lenacapavir will also be presented.
Gilead will present an overview of results from its pivotal Phase 3 PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials, which studied the efficacy and safety of lenacapavir, the company's injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention in a broad, diverse range of people globally. The trials were unblinded in June and September, respectively.
Additionally, Gilead will present five-year outcomes in new subgroup analyses from Studies 1489 (NCT02607930) and 1490 (NCT02607956), which assessed the safety and efficacy of Biktarvy compared to Triumeq (ABC/DTG/3TC) and dolutegravir 50 mg (DTG) + emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg, DTG+F/TDF. The first analysis evaluated the safety and efficacy of Biktarvy in treatment naïve PWH aged 50 or older, providing data to inform treatment decisions in this increasing proportion of PWH with a greater burden of age-related comorbidities. The second analysis evaluated the safety and efficacy of Biktarvy in treatment-naïve Black adults, a population that has historically been underrepresented in clinical studies despite the disproportionate impact of HIV on Black communities.
Gilead will also present three-year outcomes from the CAPELLA study (NCT04150068), which evaluated twice-yearly subcutaneous dosing of Sunlenca •(lenacapavir) in combination with an optimized background regimen in people with multi-drug resistant HIV.
HIV prevention data will include an analysis of newly initiated pre-exposure prophylaxis (PrEP) use in priority populations with unmet needs for PrEP in the U.S.
Additional HIV research findings include a presentation of survey data reporting current real-world trends for PWH with ART resistance mutations and utilization of healthcare resources in addition to the impact on efficacy, safety and clinical outcomes.
|
| |
|
|
|
|
|
